Event
Connect with Quotient Sciences at the upcoming BIO International Convention 2023 in Boston, MA between June 5-8.
Schedule a meeting
Early Development
Accelerating molecules through to proof-of-concept
Simplify early development and accelerate to proof-of-concept with the help of Quotient Sciences
Proof-of-concept
Proof-of-concept (POC) is a key milestone in the development of a new drug candidate. We understand the transition to POC needs to be fast and cost-effective.
With fully integrated capabilities from first-in-human testing to seamless drug product supply for patient trials, we simplify early development and accelerate molecules through to POC.
Resources
Read our related case studies
-
Info SheetIntegrated Programs: Early DevelopmentSimplify early development and accelerate to Proof-of Concept Proof-of-Concept (POC) is a key milestone in the development of a new drug candidate. At Quotient Sciences, we understand the increasing pressures on R&D budgets, therefore the need to transition molecules through early development to POC needs to be fast and cost-effective.
-
Case StudiesBioCryst PharmaceuticalsBioCryst Pharmaceuticals is taking advantage of Quotient Sciences’ Translational Pharmaceutics® platform and First-In-Human program for the development of BCX4161, a promising candidate for the treatment of hereditary angioedema.
-
Case StudiesStealth BioTherapeuticsStealth BioTherapeutics is using real-time sterile manufacturing to enable a new route of administration.
-
Case StudiesMEI PharmaMEI Pharma has leveraged Quotient's Translational Pharmaceutics® platform to expedite development of its next-generation cancer therapy ME-401.
Ready to get started?
Connect with our experts